Regular
NAV (05-Sep-24)
Returns (Since Inception)
Fund Size
₹1,056 Cr
Expense Ratio
2.18%
ISIN
INF277K016A9
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
28 Dec 2015
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+54.99%
+54.79% (Cat Avg.)
3 Years
+19.57%
+18.09% (Cat Avg.)
5 Years
+28.52%
+29.12% (Cat Avg.)
Since Inception
+13.95%
— (Cat Avg.)
Equity | ₹1,024.27 Cr | 96.99% |
Others | ₹31.75 Cr | 3.01% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹138.29 Cr | 13.10% |
Aurobindo Pharma Ltd | Equity | ₹106.27 Cr | 10.06% |
Lupin Ltd | Equity | ₹97.55 Cr | 9.24% |
Dr Reddy's Laboratories Ltd | Equity | ₹72.66 Cr | 6.88% |
Cipla Ltd | Equity | ₹64.09 Cr | 6.07% |
Zydus Lifesciences Ltd | Equity | ₹58.78 Cr | 5.57% |
Divi's Laboratories Ltd | Equity | ₹51.68 Cr | 4.89% |
Fortis Healthcare Ltd | Equity | ₹42.92 Cr | 4.06% |
Alkem Laboratories Ltd | Equity | ₹39.95 Cr | 3.78% |
Apollo Hospitals Enterprise Ltd | Equity | ₹38.97 Cr | 3.69% |
Cash / Net Current Asset | Cash - Collateral | ₹27.73 Cr | 2.63% |
Ajanta Pharma Ltd | Equity | ₹25.53 Cr | 2.42% |
Medi Assist Healthcare Services Ltd | Equity | ₹25.08 Cr | 2.38% |
Orchid Pharma Ltd | Equity | ₹24.48 Cr | 2.32% |
FDC Ltd | Equity | ₹24.01 Cr | 2.27% |
Torrent Pharmaceuticals Ltd | Equity | ₹22.49 Cr | 2.13% |
HealthCare Global Enterprises Ltd | Equity | ₹19.99 Cr | 1.89% |
Ipca Laboratories Ltd | Equity | ₹18.63 Cr | 1.76% |
Wockhardt Ltd | Equity | ₹17.84 Cr | 1.69% |
Jupiter Life Line Hospitals Ltd | Equity | ₹14.22 Cr | 1.35% |
Sanofi India Ltd | Equity | ₹12.67 Cr | 1.20% |
Piramal Pharma Ltd | Equity | ₹10.5 Cr | 0.99% |
Akums Drugs And Pharmaceuticals Ltd | Equity | ₹10 Cr | 0.95% |
Coromandel International Ltd | Equity | ₹9.97 Cr | 0.94% |
Indoco Remedies Ltd | Equity | ₹9.2 Cr | 0.87% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹9.18 Cr | 0.87% |
Syngene International Ltd | Equity | ₹8.65 Cr | 0.82% |
Mankind Pharma Ltd | Equity | ₹8.41 Cr | 0.80% |
Procter & Gamble Health Ltd | Equity | ₹8.4 Cr | 0.80% |
Medplus Health Services Ltd | Equity | ₹8.08 Cr | 0.76% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹6.82 Cr | 0.65% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹6.71 Cr | 0.64% |
Ami Organics Ltd | Equity | ₹6.69 Cr | 0.63% |
Deepak Nitrite Ltd | Equity | ₹5.54 Cr | 0.52% |
A) Repo | Cash - Repurchase Agreement | ₹4.02 Cr | 0.38% |
Large Cap Stocks
37.55%
Mid Cap Stocks
39.82%
Small Cap Stocks
15.65%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹985.25 Cr | 93.30% |
Basic Materials | ₹22.2 Cr | 2.10% |
Standard Deviation
This fund
15.49%
Cat. avg.
15.96%
Lower the better
Sharpe Ratio
This fund
0.85
Cat. avg.
0.79
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.44
Higher the better
Since March 2021
ISIN | INF277K016A9 | Expense Ratio | 2.18% | Exit Load | No Charges | Fund Size | ₹1,056 Cr | Age | 28 Dec 2015 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | Nifty Pharma TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹14.97 Cr | 55.2% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹791.70 Cr | 56.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹791.70 Cr | 54.1% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹31.78 Cr | 52.5% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹183.39 Cr | 55.6% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹183.39 Cr | 52.7% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2560.38 Cr | 53.4% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2560.38 Cr | 51.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹798.61 Cr | 52.8% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.87 Cr | 51.4% |
Total AUM
₹1,76,658 Cr
Address
Mafatlal Centre, 9th Floor, Mumbai, 400 021
Your principal amount will be at Very High Risk